Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

CHMP opinion recommends bortezomib for use in mantle cell lymphoma

CHMP opinion recommends bortezomib for use in mantle cell lymphoma

Narrow subset of cells is responsible for metastasis in multiple myeloma

Narrow subset of cells is responsible for metastasis in multiple myeloma

ASH 2014: Phase II trial shows maintenance with ixazomib in newly diagnosed multiple myeloma may be feasible

ASH 2014: Phase II trial shows maintenance with ixazomib in newly diagnosed multiple myeloma may be feasible

ASH 2014: Low-molecular-weight heparin more effective than warfarin in preventing clot recurrence in cancer patients

ASH 2014: Low-molecular-weight heparin more effective than warfarin in preventing clot recurrence in cancer...

ASH 2014: Anticoagulation after incidental pulmonary embolism may reduce risk of clot recurrence in cancer patients

ASH 2014: Anticoagulation after incidental pulmonary embolism may reduce risk of clot recurrence in cancer patients

ASH 2014: Children with rare leukaemia have better-than-expected outcomes after tailored treatment

ASH 2014: Children with rare leukaemia have better-than-expected outcomes after tailored treatment

ASH 2014: First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia

ASH 2014: First randomised evidence for benefit from adding a tyrosine kinase inhibitor in acute myeloid leukaemia

ASH 2014: Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

ASH 2014: Targeted therapy effective in elderly patients with Philadelphia-positive acute lymphocytic leukaemia

ASH 2014: Chemo-free treatment approach demonstrates positive responses in leukaemia patients

ASH 2014: Chemo-free treatment approach demonstrates positive responses in leukaemia patients

ASH 2014: Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

ASH 2014: Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase...

More from ecancer